Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Pharmaceutics 2014, 6(2), 333-353; doi:10.3390/pharmaceutics6020333
Review

Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers

1
, 1
, 1
, Jr. 2,3
 and 1,4,5,6,*
Received: 4 March 2014; in revised form: 25 April 2014 / Accepted: 4 June 2014 / Published: 20 June 2014
(This article belongs to the Special Issue Liposome Technologies)
View Full-Text   |   Download PDF [1292 KB, uploaded 20 June 2014]
Abstract: Nanomedicine is making groundbreaking achievements in drug delivery. The versatility of nanoparticles has given rise to its use in respiratory delivery that includes inhalation aerosol delivery by the nasal route and the pulmonary route. Due to the unique features of the respiratory route, research in exploring the respiratory route for delivery of poorly absorbed and systemically unstable drugs has been increasing. The respiratory route has been successfully used for the delivery of macromolecules like proteins, peptides, and vaccines, and continues to be examined for use with small molecules, DNA, siRNA, and gene therapy. Phospholipid nanocarriers are an attractive drug delivery system for inhalation aerosol delivery in particular. Protecting these phospholipid nanocarriers from pulmonary immune system attack by surface modification by polyethylene glycol (PEG)ylation, enhancing mucopenetration by PEGylation, and sustaining drug release for controlled drug delivery are some of the advantages of PEGylated liposomal and proliposomal inhalation aerosol delivery. This review discusses the advantages of using PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery through the nasal and pulmonary routes as inhalation aerosols.
Keywords: PEGylated liposomes; PEGylated micelles; sterically stabilized nanoparticles; nasal; lung; aerosol; solid-state PEGylated bilayer nanocarriers; PEGylated inhalation powders PEGylated liposomes; PEGylated micelles; sterically stabilized nanoparticles; nasal; lung; aerosol; solid-state PEGylated bilayer nanocarriers; PEGylated inhalation powders
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Muralidharan, P.; Mallory, E.; Malapit, M.; Hayes, D., Jr.; Mansour, H.M. Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Pharmaceutics 2014, 6, 333-353.

AMA Style

Muralidharan P, Mallory E, Malapit M, Hayes D, Jr, Mansour HM. Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Pharmaceutics. 2014; 6(2):333-353.

Chicago/Turabian Style

Muralidharan, Priya; Mallory, Evan; Malapit, Monica; Hayes, Don, Jr.; Mansour, Heidi M. 2014. "Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers." Pharmaceutics 6, no. 2: 333-353.



Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert